ZBIO

Zenas BioPharma, Inc. (ZBIO) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies. The company completed its Initial Public Offering (IPO) on September 16, 2024, listing on the Nasdaq Global Select Market under the symbol "ZBIO." The company has no products approved for commercial sale and has incurred substantial losses since inception.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to zero in Q3 2024 compared to $50.0 million in Q3 2023. The prior year revenue was a one-time upfront payment from a collaboration with Bristol-Myers Squibb (BMS) recognized in 2023.
• Increased Operating Loss: The company reported a net loss of $38.6 million for Q3 2024, a reversal from net income of $35.6 million in Q3 2023. This is primarily due to the absence of the BMS revenue and a significant increase in operating expenses.
• R&D Expense Surge: Research and Development expenses increased to $33.5 million in Q3 2024 from $9.4 million in Q3 2023. This $24.2 million increase was driven by clinical trial costs and manufacturing for the lead candidate, obexelimab.
• Capital Structure Transformation: Following the IPO, all outstanding convertible preferred stock converted to common stock. Additionally, a $20.0 million convertible note held by BMS was converted into Series C preferred stock (and subsequently common stock) in May 2024, eliminating debt obligations.
• Liquidity Position: Cash and cash equivalents increased from $56.9 million at year-end 2023 to $360.0 million at Q3 2024, bolstered by $234.4 million in net IPO proceeds and $178.4 million from a Series C financing.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring significant and increasing losses for the foreseeable future. The company projects that its current cash, cash equivalents, and investments of $386.8 million will be sufficient to fund operations and capital expenditures into the fourth quarter of 2026.
• Development Pipeline: The company is advancing obexelimab in a Phase 3 trial for IgG4-RD and has initiated Phase 2 trials for Multiple Sclerosis (MS) and Systemic Lupus Erythematosus (SLE) in Q3 2024.
• Subsequent Events: In October 2024, the company entered a Novation Agreement with Tenacia Biotechnology, transferring rights to certain product candidates (ZB005) in exchange for a $5.0 million upfront fee and up to $86.0 million in potential milestones.
• Key Risks:
  • Capital Needs: Failure to obtain additional financing could force delays or termination of product development.
  • Clinical Uncertainty: Clinical trials may fail to demonstrate efficacy or safety, or results may not predict future outcomes.
  • Supply Chain: Reliance on a single third-party manufacturer (WuXi Biologics in China) for drug substance and product creates supply chain and geopolitical risks, including potential impacts from the proposed BIOSECURE Act.
  • Regulatory: No assurance of regulatory approval for any product candidates.

Investor Verification Checklist

• Runway Validation: Verify the $386.8 million liquidity figure and the management's projection of funding sufficiency through Q4 2026 against current burn rates.
• Obexelimab Progress: Monitor enrollment and data readouts for the Phase 3 IgG4-RD trial and the newly initiated Phase 2 trials for MS and SLE.
• Manufacturing Strategy: Assess the status of establishing alternative manufacturing sources in the U.S. to mitigate reliance on WuXi Biologics and potential regulatory restrictions.
• Collaboration Revenue: Track the status of the BMS collaboration for potential future milestone payments and the Tenacia agreement for the $5.0 million upfront fee recognition.
• Dilution: Review the impact of the IPO and preferred stock conversion on share count (41.8 million shares outstanding as of Oct 31, 2024) and future equity compensation plans.